The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.
- The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.
- In the pilot animal study, an adult version of Sigyn Therapywas administered to two porcine (pig) subjects (each ~ 40 kilos) to evaluate the feasibility of a therapeutic protocol designed to support subsequent clinical studies.In the study, Sigyn Therapy was deployed on a standard dialysis hardware system and utilized conventional blood-tubing set configurations.
- Craig Roberts, Chief Technical Officer at Sigyn Therapeutics, added, We are pleased with the results of our pilot study, which provides us with clinical evidence that our device can be safely used without complications or adverse events.
- This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.